Data Sheet (Cat.No.T10218)

TargetMol

Abatacept

Chemical Properties

CAS No. : 332348-12-6

Formula:

Molecular Weight:

Storage: Store at low temperature
Store at -20°C
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Abatacept is a soluble recombinant fusion protein, which consists of extracellular domain of human CTLA-4 and human Fc segment. Abatacept specifically blocks CD28-mediated costimulatory signals by binding to CD80 and CD86 on the surface of antigen presenting cells with high affinity, thus inhibiting T cell activation. Abatacept is often used to study rheumatoid arthritis, autoimmune reaction and immune disorder caused by LRBA deficiency.
Targets(IC50)	Immunology/Inflammation related
In vitro	In co-culture assays of primary CD4+ T cells and APCs, Abatacept (100 ug/mL) blocked the CD80/86:CD28 costimulatory axis and inhibited T-cell proliferation [3]. In ex vivo analysis of cells from patients with LRBA deficiency, Abatacept modulated CTLA-4 expression levels and restored regulatory T cell function [1].
In vivo	In a rat model of collagen-induced arthritis, subcutaneous administration of Abatacept (0.1, 1, 10 mg/kg) led to dose-dependent reduction in paw edema [2]. In mouse T-cell priming models, systemic administration of Abatacept (0.5 mg/mouse) inhibited antigen-specific T-cell activation and expansion [3].
Animal Research	Animal Model: Male Lewis rats (6-9 weeks old) with weights of 150-175 g. Dosage: 10 mg/kg (i.v.), 20 mg/kg (s.c. single-dose), 20 mg/kg (SC Multiple-dose) on day 21 with 10 mg/kg SC doses on days 23, 25, 27, and 29. Administration: i.v. or s.c. [2]

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481